Not a good buy right now for an impatient buyer: price is breaking/pressing below near-term support while momentum is still deteriorating.
Oversold (RSI-6 ~14.8) can spark a short bounce, but MACD is still expanding negatively—this is more consistent with a falling-knife setup than a clean dip-buy.
Options positioning is call-skewed, but implied vol is extremely elevated (IV percentile ~92), suggesting event/uncertainty pricing rather than confident upside.
Near-term catalyst risk: earnings on 2026-02-27 pre-market; with hedge funds selling and losses still present, timing is unfavorable for a “buy now” approach.
Trend/momentum: Bearish. MACD histogram at -0.242 and negatively expanding indicates downside momentum is still strengthening.
RSI: RSI_6 at 14.829 signals deeply oversold; a bounce is possible, but oversold can persist in downtrends.
Moving averages: Converging MAs suggests consolidation after a decline, but not yet a confirmed reversal.
Key levels: Pivot 27.025 overhead (first reclaim level). Support S1 25.703 and S2 24.886; post-market at 25.53 is already below S1, increasing odds of a test toward ~24.89.
Practical read: Any bounce that fails below ~27.0–28.3 looks like a sell-the-rip zone rather than a new uptrend.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/sentiment: Put/Call OI ratio 0.24 is call-heavy (bullish skew), while today’s put volume is 0 and call volume is 22 (thin, not broad conviction).
Volatility: 30D IV 62.55 vs historical vol 30.6; IV percentile 92.43 suggests options are very expensive and the market is pricing elevated uncertainty.
Flow/participation: Today’s volume (22) is far below 5D/10D average option volume (336/404), so the skew may be less informative than usual.
Interpretation: Sentiment leans bullish via open interest, but elevated IV + low volume looks more like “uncertainty priced in” than a strong smart-money upside bet.
Technical Summary
Sell
7
Buy
7
Positive Catalysts
Oversold technical condition (RSI) can trigger a short-term rebound.
Revenue growth remains positive: 2025/Q3 revenue up 17.18% YoY.
Gross margin improved in 2025/Q3 (39.83%, +15.32% YoY), suggesting some operating/quality improvement.
Potential event-driven move around earnings (2026-02-27 pre-market).
Neutral/Negative Catalysts
signals uncertainty and can coincide with sharp moves (not ideal for an impatient entry).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $84.07M, +17.18% YoY (top-line growth is improving).
Profitability: Net income -$6.61M, down -54.89% YoY (losses widened).
EPS: -0.21, down -56.25% YoY (earnings power deteriorated).
Gross margin: 39.83%, +15.32% YoY (margin improvement is a bright spot, but not yet translating into profits).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Most recent update (2025-11-11): Piper Sandler raised price target to $30 from $21, maintained Neutral.
Trend: Price target moved up, but rating stayed Neutral—Wall Street is acknowledging improved outlook/quarterly results, without upgrading to a clear Buy.
Pros view: Improved targets and margin trends suggest upside potential if execution continues.
Cons view: Neutral stance implies limited near-term confidence; combined with hedge-fund selling and worsening EPS, the Street is not broadly signaling “buy now.”
Wall Street analysts forecast FLGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FLGT is 32.5 USD with a low forecast of 30 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FLGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FLGT is 32.5 USD with a low forecast of 30 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 23.710
Low
30
Averages
32.5
High
35
Current: 23.710
Low
30
Averages
32.5
High
35
Piper Sandler
Neutral
maintain
$21 -> $30
AI Analysis
2025-11-11
Reason
Piper Sandler
Price Target
$21 -> $30
AI Analysis
2025-11-11
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Fulgent Genetics to $30 from $21 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.
UBS
Neutral -> Buy
upgrade
$20 -> $30
2025-08-05
Reason
UBS
Price Target
$20 -> $30
2025-08-05
upgrade
Neutral -> Buy
Reason
UBS upgraded Fulgent Genetics to Buy from Neutral with a price target of $30, up from $20, after assuming coverage of the name. The firm sees potential for upside in the company's Precision Diagnostics unit, which represents 60% of total sales, due to share gain opportunities and a more favorable reimbursement landscape. In addition, Fulgent's Anatomic Pathology segment has started to recover and is no longer dilutive to growth, the analyst tells investors in a research note. UBS sees the company sustaining 10% revenue growth in 2025 and beyond.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FLGT
